Cargando…

Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis

BACKGROUND: Upfront high-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains a profitable strategy for newly diagnosed multiple myeloma (MM) patients in the context of novel agents. However, current knowledge demonstrates a discrepancy between progression-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chi-Maw, Chang, Lih-Chyun, Shau, Wen-Yi, Chen, Chi-Ling, Yao, Chi-Yuan, Tien, Feng-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190007/ https://www.ncbi.nlm.nih.gov/pubmed/37193978 http://dx.doi.org/10.1186/s12885-023-10907-1

Ejemplares similares

P1299: OUTCOMES OF YOUNG ADULTS (AGED ≤40 YEARS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
por: Geng, Chuanying, et al.
Publicado: (2022)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
por: Bove, Virginia, et al.
Publicado: (2021)

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
por: Pulte, Elizabeth Dianne, et al.
Publicado: (2018)

Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation
por: Fan, Liping, et al.
Publicado: (2017)

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation
por: Ma, Kewa, et al.
Publicado: (2021)

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
por: Mian, Owais, et al.
Publicado: (2023)

PB2036: RISK AND PATTERN OF INFECTIONS IN NEWLY DIAGNOSED PATIENTS OF MULTIPLE MYELOMA VACCINATED UPFRONT AGAINST PNEUMOCOCCUS & INFLUENZA
por: VA, A., et al.
Publicado: (2022)

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
por: Côté, Julie, et al.
Publicado: (2023)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
por: Gu, Jingli, et al.
Publicado: (2021)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
por: Luoma, Sini, et al.
Publicado: (2019)

Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience
por: Nguyen, Phillip C., et al.
Publicado: (2022)

Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
por: Shrestha, Bikram, et al.
Publicado: (2017)

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
por: Ocio, Enrique M., et al.
Publicado: (2023)

A Case of Multiple Myeloma in a 17-Year-Old Girl Treated with Autologous Hematopoietic Stem Cell Transplantation (ASCT)
por: Van Man, Huynh, et al.
Publicado: (2019)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation
por: Ray, Gopal Krushna, et al.
Publicado: (2021)

P17 CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
por: Pilerci, S., et al.
Publicado: (2023)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation
por: Çiftçiler, Rafiye, et al.
Publicado: (2021)

Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
por: Chung, David J., et al.
Publicado: (2023)

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
por: Bahlis, N J, et al.
Publicado: (2017)

Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study: Treatment pattern and outcomes in patients with multiple myeloma
por: He, Jianming, et al.
Publicado: (2020)

Total Marrow Irradiation as Part of Autologous Stem Cell Transplantation for Asian Patients with Multiple Myeloma
por: Lin, Shih-Chiang, et al.
Publicado: (2013)

Double Autologous Stem Cell Transplantation for Multiple Myeloma: A Korean Single Center Study
por: Ko, Ock Bae, et al.
Publicado: (2005)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
por: Zamagni, Elena, et al.
Publicado: (2020)

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
por: Chim, C. S., et al.
Publicado: (2010)

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
por: Gagelmann, Nico, et al.
Publicado: (2018)

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
por: Al-Anazi, Khalid Ahmed
Publicado: (2012)

Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tosi, P., et al.
Publicado: (2012)

Complete response after autologous stem cell transplant in multiple myeloma
por: Kumar, Lalit, et al.
Publicado: (2014)

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma
por: Halpin, Sean N, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i6ot85t5rglomrndg16vrsa22s